Literature DB >> 29934610

Quizartinib tested in patients with high-risk AML.

Peter Sidaway1.   

Abstract

Entities:  

Year:  2018        PMID: 29934610     DOI: 10.1038/s41571-018-0061-8

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.

Authors:  LaQuita M Jones; Katelyn Melgar; Lyndsey Bolanos; Kathleen Hueneman; Morgan M Walker; Jian-Kang Jiang; Kelli M Wilson; Xiaohu Zhang; Jian Shen; Fan Jiang; Patrick Sutter; Amy Wang; Xin Xu; Gregory J Tawa; Scott B Hoyt; Mark Wunderlich; Eric O'Brien; John P Perentesis; Daniel T Starczynowski; Craig J Thomas
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.